昂利康(002940.SZ):擬與公司技術團隊組建合資公司 以在生物發酵、酶工程等合成生物技術的研發和產業化應用等方面進行投資
格隆匯3月31日丨昂利康(002940.SZ)公佈,公司於2023年3月30日召開的第三屆董事會第二十六次會議,審議通過了《關於對外投資設立子公司的議案》,同意公司與喬曉光、王孟強、郭靖寧、杜二洪、鄧文鋒(簡稱“技術團隊”)簽訂《關於組建合資公司的合同》,擬通過組建合資公司在生物發酵、酶工程等合成生物技術的研究、開發和產業化應用等方面進行投資。
基於公司發展戰略和未來研發佈局,為增強公司的可持續發展能力和核心競爭力,實現公司在合成生物學領域的業務佈局,公司擬與公司技術團隊喬曉光、王孟強、郭靖寧、杜二洪、鄧文鋒共同設立合資公司,依託國內知名院校、機構研發平台,運用先進的合成生物學技術,構建高效菌羣,同時充分發揮技術團隊的規模放大、產業化核心優勢,在抗生素藥物、甾體化合物、食品和保健品、生物酶等產品領域進行嘗試,建立可持續經營的產業體系和新的利潤增長極。
本次擬設立的合資公司為浙江昂利康錦和生物技術有限公司(暫定名,最終以經工商登記主管部門核准登記的公司名稱為準,簡稱“錦和生物”或“合資公司”),認繳出資總額為人民幣5000萬元,各方均以自有資金出資,其中公司持有80%股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.